Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 401–500 of 799
Eit, R. E., Itani, A. R., Nassar, F. J., Rasbieh, N. G., Jabbour, M. N., Santina, A., Zaatari, G. S., Mahon, F., Bazarbachi, A. A., & Nasr, R. (2019) · Cancer · doi:10.1002/cncr.32130 · Cited by 16
“It is important to note that such therapies cannot cure patients with Philadelphia chromosome–positive leukemia because of the persistence of leukemiainitiating cells (LICs),(17,18) a phenomenon that has been explained by several resistance mechanisms such as the maintenance of quiescence(19) and the lack of addiction…”
BackgroundWei, L., Yang, Y., Gupta, P., Wang, A., Zhao, M., Zhao, Y., Qu, M., Ke, Y., Liu, Y., Liu, H., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.008 · Cited by 16
“Known attributors responsible for resistance to imatinib in CML are the point mutations of the BCR-ABL kinase domain,(9,10) the amplification of the BCR-ABL gene,(11) and the insensitivity of leukemia stem cells to imatinib.(12,13)Mutation in the kinase domain of BCR-ABL is believed to be the most predominant, which g…”
BackgroundLi, S., Wang, L., Li, Y., Zhu, X., Zhong, L., Lu, L., Zhang, W., Liu, B., Xie, G., & Feng, W. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.07.027 · Cited by 16
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
Wieczorek, A., & Uharek, L. (2015) · Biomarker Insights · doi:10.4137/bmi.s22431 · Cited by 16
Yuda, J., Miyamoto, T., Odawara, J., Ohkawa, Y., Semba, Y., Hayashi, M., Miyamura, K., Tanimoto, M., Yamamoto, K., Taniwaki, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13353 · Cited by 19
Novel Drug Therapies in Myeloid Leukemia: a Patent Review
Horne, G. A., Kinstrie, R., & Copland, M. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.3 · Cited by 18
Elucidation of protein interactions necessary for the maintenance of the BCR–ABL signaling complex
Gregor, T., Bosakova, M. K., Niţă, A., Abraham, S. P., Fafílek, B., Cernohorsky, N. H., Ryneš, J., Foldynová-Trantírková, S., Žáčková, D., Mayer, J., et al. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03397-7 · Cited by 16
Chávez‐González, A., Centeno-Llanos, S., Moreno-Lorenzana, D., Sandoval-Esquivel, M. A., Avilés‐Vázquez, S., Gómez, M. E. B., Ruíz-Azuara, L., Ayala‐Sánchez, M., Torres-Martinez, H., & Mayani, H. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.11.001 · Cited by 16
Oncogenes and the Origins of Leukemias
Brown, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042293 · Cited by 16
“CML-LSCs are also resistant to the tyrosine kinase inhibitors, such as imatinib, that are used to treat CML and other cancers [63,81].”
BackgroundClinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia
Wu, A., Liu, X., Fruhstorfer, C., & Jiang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063307 · Cited by 16
Laganà, A., Scalzulli, E., Bisegna, M. L., Ielo, C., Martelli, M., & Breccia, M. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2440776 · Cited by 20
“Many mechanisms are currently recognized as driving the persistence of CML LSCs [40,41], the extensive dissertation on which is beyond the scope of this review.”
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers
Sicuranza, A., Cavalleri, A., & Bernardi, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546813 · Cited by 17
Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
Burchert, A. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0196-8 · Cited by 17
“BCR-ABL positive progenies and stem cells persist [14–16•] despite the fact that their BCR-ABL kinase activity is potently inhibited [17–19].”
BackgroundMolecular signatures of chronic myeloid leukemia stem cells
Chen, Y., & Li, S. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-21 · Cited by 18
“Primitive human CML cells are insensitive to imatinib treatment and therapies that biochemically target BCR-ABL kinase activity will not eliminate CML stem cells [18].”
BackgroundTherapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
Parting, O., Langer, S. K., Kuepper, M. K., Wessling, C., Li, S., Braunschweig, T. A., Chatain, N., Maié, T., Costa, I. G., Crysandt, M. M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0977-8 · Cited by 15
KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor
Banerjee, S., Yoon, H., Ting, S., Tang, C., Yebra, M., Wenzel, A. T., Yeerna, H., Mesirov, J. P., Wechsler‐Reya, R. J., Tamayo, P., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0973 · Cited by 15
“This model mirrors an established mechanism of CML disease persistence in which CML stem progenitors have been shown to be quiescent, stem-like cells that exhibit IM resistance (67).”
BackgroundKaehler, M., Litterst, M., Kolarova, J., Böhm, R., Bruckmueller, H., Ammerpohl, O., Cascorbi, I., & Nagel, I. (2022) · Oncology Reports · doi:10.3892/or.2022.8355 · Cited by 17
Karvela, M., Helgason, G. V., & Holyoake, T. L. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.10 · Cited by 18
Mancini, M., Leo, E., Campi, V., Castagnetti, F., Zazzeroni, L., Gugliotta, G., Santucci, M. A., & Martinelli, G. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.010 · Cited by 16
Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Kuroda, J., Shimura, Y., Yamamoto‐Sugitani, M., Sasaki, N., & Taniwaki, M. (2012) · Current Cancer Drug Targets · doi:10.2174/156800913804486638 · Cited by 15
The Biology and Pathogenesis of Chronic Myeloid Leukemia
Chereda, B., & Melo, J. V. (2016) · Hematologic malignancies · doi:10.1007/978-3-319-33198-0_2 · Cited by 15
TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA.
Bhatia, R. (2019) · PubMed Central · Cited by 15
CD26/DPP-4 in Chronic Myeloid Leukemia
Sicuranza, A., Raspadori, D., & Bocchia, M. (2022) · Cancers · doi:10.3390/cancers14040891 · Cited by 15
“Keywords: CD26; LSCs; CML; BCR-ABL; TKIs; TFR”
BackgroundInfluentialYen, R., Grasedieck, S., Wu, A., Lin, H., Su, J., Rothe, K., Nakamoto, H., Forrest, D. L., Eaves, C. J., & Jiang, X. (2022) · Leukemia · doi:10.1038/s41375-022-01680-4 · Cited by 15
Chorzalska, A. D., Salloum, I., Shafqat, H., Khan, S. M., Marjon, P., Treaba, D. O., Schorl, C., Morgan, J. W., Bryke, C. R., Falanga, V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.120 · Cited by 15
“In addition, detailed mechanistic studies of imatinib mesylate (IM) resistance and persistence of Bcr-Abl-containing hematopoietic stem cells (HSCs) have shown that primitive CML cells are capable of survival in the absence of Bcr-Abl kinase activity (2, 7).”
BackgroundAdnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101521 · Cited by 14
Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia
Joshi, K., Zhang, L., Breslin, P., & Zhang, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_5 · Cited by 16
Ge, Y., Xu, X., Yang, B., Chen, Z., & Cheng, R. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.13.5455 · Cited by 14
“In addition, imatnib could not eliminate the primitive leukemia stem cells, leading to the potential risk of initiation, drug resistance and relapse of CML (Corbin et al., 2011).”
BackgroundComparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia
Kayabaşı, Ç., Okcanoğlu, T. B., Yelken, B. Ö., Aşık, A., Süslüer, S. Y., Avcı, Ç. B., Saydam, G., & Gündüz, C. (2017) · Gene · doi:10.1016/j.gene.2017.09.036 · Cited by 16
Trinh, A., Khamari, R., Fovez, Q., Mahon, F., Turcq, B., Bouscary, D., Maboudou, P., Curt, M. J.-C., Coiteux, V., Germain, N., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101410 · Cited by 14
“Recently a therapeutic drug combination targeting mitochondrial metabolism demonstrated its efficacy against LSCs in patients with AML [2,40].”
BackgroundMethodInfluentialHematopoietic and Chronic Myeloid Leukemia Stem Cells: Multi-Stability versus Lineage Restriction
Brown, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113570 · Cited by 17
“However, the kinase activity is not required for the survival and self-renewal of CML LSCs because they are insensitive to the second-generation inhibitors dasatinib, nilotinib, and bosutinib that are used to treat patients, and their persistence leads to minimal residual disease in patients [32,33].”
BackgroundGardner, L. A., Klawitter, J., Gregory, M. A., Zaberezhnyy, V., Baturin, D., Pollyea, D. A., Takebe, N., Christians, U., Gore, L., DeGregori, J. V., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23776 · Cited by 14
“tive leukemia progenitor cells to IM [7] or the non-addiction of hematopoietic stem cells to BCR-ABL1 [8].”
BackgroundaSIRTing Control over Cancer Stem Cells
Ito, T., Zimdahl, B., & Reya, T. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.014 · Cited by 14
“Emerging evidence suggests that differentiated CML cells are addicted to ABL and can be eliminated by kinase inhibitors, while cancer stem cells can become ABL independent and thus persist despite therapy (Graham et al., 2002; Corbin et al., 2011).”
BackgroundSuppression of autophagy by BCR/ABL
Calabretta, B., & Salomoni, P. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/278 · Cited by 14
Targeting Disease Persistence in Gastrointestinal Stromal Tumors
Ördög, T., Zörnig, M., & Hayashi, Y. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0298 · Cited by 14
Stem cell maintenance and disease progression in chronic myeloid leukemia
Ito, T. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1318-8 · Cited by 17
“Recently, it has become clear that while differentiated CML cells are dependent on BCR–ABL1 activity for their survival and therefore remain sensitive to kinase inhibition, CML stem cells do not rely on its activity and persist despite the effective inhibition of the BCR–ABL1 by TKIs [18–20].”
BackgroundCurrent attempts to implement siRNA-based RNAi in leukemia models
Uludağ, H., Landry, B. K., Valencia‐Serna, J., Remant, K. C., & Meneksedag‐Erol, D. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.018 · Cited by 14
Moorthi, S., Burns, T. A., Yu, G., & Luberto, C. (2018) · The FASEB Journal · doi:10.1096/fj.201701016r · Cited by 15
Li, W., Ji, M., Lu, F., Pang, Y., Dong, X., Zhang, J., Li, P., Ye, J., Zang, S., Ma, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0900-7 · Cited by 14
Ji, D., Zhang, P., Ma, W., Fei, Y., Xue, W., Wang, Y., Zhang, X., Zhou, H., & Zhao, Y. (2019) · Oncogene · doi:10.1038/s41388-019-0998-9 · Cited by 14
Yamaguchi, H., Takezako, N., Ohashi, K., Oba, K., Kumagai, T., Kozai, Y., Wakita, H., Yamamoto, K., Fujita, A., Igarashi, T., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-019-02801-z · Cited by 15
Feng, C., Guo, J., Li, G., Ye, B., & Zou, L. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128972 · Cited by 13
Massimino, M., Vigneri, P. G., Stella, S., Tirrò, E., Pennisi, M. S., Parrinello, L., Vetro, C., Manzella, L., Stagno, F., & Raimondo, F. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235606 · Cited by 14
“the “non-oncogene addicted” property shown by leukemic stem cells [41,42].”
BackgroundPagani, I. S., Poudel, G., & Wardill, H. R. (2022) · Microorganisms · doi:10.3390/microorganisms10040713 · Cited by 13
PROTACs: The Future of Leukemia Therapeutics
Anwar, Z., Ali, M. S., Galvano, A., Perez, A., Mantia, M. L., Bukhari, I., & Świątczak, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851087 · Cited by 15
“However, drug resistance, life-long use and chances of relapse pose serious concerns (Mahon et al., 2010; Corbin et al., 2011; Cao et al., 2021).”
BackgroundRittavee, Y., Artus, J., Desterke, C., Simanic, I., de Souza, L. E. B., Riccaldi, S., Coignard, S., Ijjeh, Y., Hugues, P., Griscelli, A. B., et al. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.12.003 · Cited by 13
Targeting Chronic Myeloid Leukemia Stem Cells
Kinstrie, R., & Copland, M. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0148-8 · Cited by 14
“They showed that imatinib inhibited BCR-ABL activity to the same extent in all stem and progenitor cells tested and that even though expansion of these cells was reduced in the short term, growth factor supplementation allowed continued growth and survival even in the absence of BCR-ABL activity, suggesting primitive…”
BackgroundHorne, G. A., & Copland, M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1303477 · Cited by 15
“relying on other pathways to sustain their survival [36,37].”
BackgroundInduced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling
Zhu, D., Kong, C. S. L., Gingold, J. A., Zhao, R., & Lee, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_257 · Cited by 15
TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway
Wu, Y., Hu, Y., Yu, X., Zhang, Y., Huang, X., Chen, S., Li, Y., & Zeng, C. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.164 · Cited by 13
Ma, L., Pak, M. L., Ou, J., Yu, J., Louis, P. S., Shan, Y., Hutchinson, L., Li, S., Brehm, M. A., Zhu, L. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903550116 · Cited by 13
Khalaf, A., de Beauchamp, L., Kalkman, E. R., Rattigan, K. M., Himonas, E., Jones, J., James, D. T., Shokry, E., Scott, M. T., Dunn, K. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi5336 · Cited by 15
“We and others have shown that CML LSCs are insensitive to TKI treatment despite inhibition of BCR::ABL1 activity ( 6 , 7 ).”
BackgroundDolinska, M., Cai, H., Månsson, A., Shen, J., Xiao, P., Bouderlique, T., Li, X., Leonard, E., Chang, M. C., Gao, Y., et al. (2023) · Blood · doi:10.1182/blood.2022016896 · Cited by 25
Wu, A., Yen, R., Grasedieck, S., Lin, H., Nakamoto, H., Forrest, D. L., Eaves, C. J., & Jiang, X. (2023) · Leukemia · doi:10.1038/s41375-023-02062-0 · Cited by 13
Zhang, X., Ma, W., Xue, W., Wang, Y., Chen, P., Li, Q., Li, Y., Hu, X., Zhao, Y., & Zhou, H. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05036-8 · Cited by 12
Roy, A., Lahiry, L., Banerjee, D., Ghosh, M., & Banerjee, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076527 · Cited by 13
“and differentiation-arrested cells [2].”
The Role of Pharmacogenomics in Individualized Medicine
zu Schwabedissen, H. E. M. (2015) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-319-11719-5_7 · Cited by 14
Kong, Y., Wu, Y., Song, Y., Shi, M.-M., Cao, X.-N., Zhao, H., Qin, Y., Lai, Y., Jiang, H., Jiang, Q., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1286-5 · Cited by 12
“After 48 h of suspension culture with the vehicle (DMSO, Sigma), imatinib (5 μM, Novartis, Basel, Switzerland) [24, 33], nilotinib (5 μM, Novartis) [33], and/or ruxolitinib (300 nM, Novartis) [34, 35] treatments, an apoptosis assay was performed on the LPCs using the Annexin-V and 7-amino-actinomycin D (7-AAD) Apoptos…”
Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling
Himburg, H. A., Roos, M. M., Fang, T., Zhang, Y., Termini, C. M., Schlussel, L., Kim, M., Pang, A., Kan, J., Zhao, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129061 · Cited by 12
“Since CML stem cells that persist in patients are not BCR/ABL – addicted (58), the combination of TKI with anti-PTN antibody represents a rational therapeutic strategy.”
BackgroundStrategies For Targeting Chronic Myeloid Leukaemia Stem Cells
Carrà, G., Cartellà, A., Maffeo, B., & Morotti, A. (2019) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s228815 · Cited by 14
“In particular, TKIs are able to enter CML stem cells, to inhibit BCR-ABL, but are not able to promote their apoptosis.(14) The resistance of CML stem cells to TKIs is a very challenging issue that has been investigated in great depth over the years.”
BackgroundThe Involvement of Oxidative Stress in Chronic Myeloid Leukemia
Pascu, E. G., Găman, M., Moisă, C., ASSANI, A. D., & Găman, A. M. (2020) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/25.1/1267.1274 · Cited by 14
Ruiz, M. S., Sánchez, M. B., Bonecker, S. T., Furtado, C., Koile, D., Yankilevich, P., Cranco, S., Custidiano, M. D. R., Freitas, J., Moiraghi, B., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.612573 · Cited by 12
Kim, J.-H., Lee, S. J., Kang, K., Lee, B., Park, Y., & Kim, B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114658 · Cited by 14
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
Morotti, A., Carrà, G., Panuzzo, C., Crivellaro, S., Taulli, R., Guerrasio, A., & Saglio, G. N. (2015) · Advances in Hematology · doi:10.1155/2015/612567 · Cited by 12
Brehme, M., Koschmieder, S., Montazeri, M., Copland, M., Oehler, V. G., Radich, J. P., Brümmendorf, T. H., & Schuppert, A. (2016) · Scientific Reports · doi:10.1038/srep24057 · Cited by 12
Suknuntha, K., Thita, T., Togarrati, P. P., Ratanachamnong, P., Wongtrakoongate, P., Srihirun, S., Slukvin, I. I., & Hongeng, S. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2116-x · Cited by 12
“It is generally accepted that primitive leukemia cells are quiescent and are innately resistant to standard treatments [20, 27, 28].”
BackgroundRajamani, B. M., Benjamin, E. S. B., Abraham, A., Ganesan, S., Lakshmi, K. M., Anandan, S., Karathedath, S., Varatharajan, S., Mohanan, E., Arthur, N. B. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77140-9 · Cited by 14
Low c-Kit expression identifies primitive, therapy-resistant CML stem cells
Shah, M., Kumar, H., Qiu, S., Li, H., Harris, M., He, J., Abraham, A., Crossman, D. K., Paterson, A., Welner, R. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157421 · Cited by 11
“resist TKI treatment via BCR-ABL independent mechanisms (3-5).”
Zehtabcheh, S., Yousefi, A., Salari, S., Safa, M., Momeny, M., Ghaffari, S. H., & Bashash, D. (2021) · Cell Biology International · doi:10.1002/cbin.11557 · Cited by 11
Woessner, D. W., & Lim, C. S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300405n · Cited by 11
The one-two punch: Combination treatment in chronic myeloid leukemia
Sweet, K. L., Hazlehurst, L., & Pinilla-Ibarz, J. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.017 · Cited by 13
“ore-primitive progenitor cells that reside in the BM, howver, are resistant to TKI-induced apoptosis, even though CR-ABL1 activity is successfully inhibited [16–20].”
BackgroundMultidrug resistance in chronic myeloid leukemia
Yazıcı, M. Ü., Kiraz, Y., Kacı, F. N., Özcan, M. A., & Baran, Y. (2014) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1405-21 · Cited by 11
“It was agreed that imatinib and other TKIs could not be effective on cancer stem cells due to disease relapse in the long-term (Corbin et al., 2011; Perl and Carroll, 2011).”
BackgroundMouse models as tools to understand and study BCR-ABL1 diseases.
Koschmieder, S., & Schemionek, M. (2011) · PubMed · Cited by 12
Mancini, M., Castagnetti, F., Soverini, S., Leo, E., Benedittis, C. D., Gugliotta, G., Rosti, G., Bavaro, L., Santis, S. D., Monaldi, C., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26052 · Cited by 11
“…primitive hematopoiesis, encompassing b-catenin, Hedghog (HH), phosphatidyl-inositol 3 kinase (PIK3)-Akt axis, and protein phosphatase 2A (PP2A) [Corbin et al., 2011; Hamilton et al., 2012; O’Hare et al., 2012]. b-catenin, the best studied mediator of CML stem cell viability, is stabilized by…”
BackgroundInfluentialKidan, N., Khamaisie, H., Ruimi, N., Roitman, S., Eshel, E., Dally, N., Ruthardt, M., & Mahajna, J. A. (2017) · Journal of Cancer · doi:10.7150/jca.19633 · Cited by 13
“Interestingly, an increasing number of reports demonstrate that LSCs of Ph+ leukemia are dependent on BCRABL protein and not on its kinase activity, explaining the AKIs' inability to eradicate LSCs and eliminate residual disease [7-9].”
BackgroundXu, Y. K., Ikeda, S., Sumida, K., Yamamoto, R., Tanaka, H., & Minato, N. (2018) · Nature Communications · doi:10.1038/s41467-018-03307-8 · Cited by 11
Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy
Rodriguez, J., Iniguez, A., Jena, N., Tata, P. V., Liu, Z., Lander, A. D., Lowengrub, J. S., & Etten, R. A. V. (2023) · eLife · doi:10.7554/elife.84149 · Cited by 12
Tortorella, S. M., Hung, A., & Karagiannis, T. C. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6096 · Cited by 12
“Interestingly, however, is the finding that these CML progenitor cells are not dependent on the BCR-ABL oncoprotein for survival (71, 184).”
Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells
Poggetto, E. D., Tanturli, M., Ben‐Califa, N., Gozzini, A., Tusa, I., Cheloni, G., Marzi, I., Cipolleschi, M. G., Kashman, Y., Neumann, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1078029 · Cited by 12
MAPK-negative feedback regulation confers dependence to JAK2V617F signaling
Kesarwani, M., Kincaid, Z., Azhar, M., Menke, J., Schwieterman, J., Ansari, S., Reaves, A., Deininger, M. W., Levine, R. L., Grimes, H. L., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01959-0 · Cited by 9
Self-citationPRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis
Zhou, M., Huang, Y., Xu, P., Li, S., Chen, D., Lin, X., Bao, S., Zou, W., Pan, J., Liu, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202308586 · Cited by 12
STAT5 as a CML target: STATinib therapies?
Turhan, A. G. (2011) · Blood · doi:10.1182/blood-2011-01-332569 · Cited by 10
Leukaemic stem cells: drug resistance, metastasis and therapeutic implications.
Wong, R. S.-Y., & Cheong, S. (2012) · PubMed · Cited by 15
Huntingtin-Interacting Protein 1 Phosphorylation by Receptor Tyrosine Kinases
Ames, H. M., Wang, A. A., Coughran, A. J., Evaul, K., Huang, S., Graves, C. W., Soyombo, A. A., & Ross, T. S. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00473-13 · Cited by 11
Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
Alshareef, A. (2017) · Cancers · doi:10.3390/cancers9110148 · Cited by 11
“For instance, leukemia stem cells have been shown to utilize signaling pathways independent of BCR-ABL kinase activity for their maintenance and survival, and that these cells were insensitive to TKIs such as imatinib or dasatinib [65,66].”
BackgroundYagi, K., Shimada, A., & Sendo, T. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.022 · Cited by 10
“Therefore, it might be necessary to inhibit other signaling pathways in addition to BCR-ABL kinase activity (Corbin et al., 2011; Colavita et al., 2013).”
BackgroundMasamoto, Y., & Kurokawa, M. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.03.05 · Cited by 10
“CML LSCs, unlike their differentiated progenies, don’t depend on BCR-ABL signaling for their survival, in other words, they are free from oncogene addiction (11).”
BackgroundMatsushita, M. (2021) · Cancers · doi:10.3390/cancers13215435 · Cited by 10
Nagai, Y., Kawahara, M., Sugino, N., Shimazu, Y., Hishizawa, M., Yamashita, K., Kadowaki, N., & Takaori‐Kondo, A. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-6 · Cited by 10
Zhou, S., Zhu, X., Liu, W., Cheng, F., Zou, P., You, Y., Xiao, Y., Guo, A., & Zhu, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.092 · Cited by 10
Stuckey, R., López-Rodríguez, J. F., Sánchez-Sosa, S., Segura-Díaz, A., Sánchez-Farías, N., Bilbao, C., & Gómez‐Casares, M. T. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i12.996 · Cited by 10
Mukaida, N., Tanabe, Y., & Baba, T. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00030-7 · Cited by 10
Antagonizing RARγ Drives Necroptosis of Cancer Stem Cells
Brown, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094814 · Cited by 11
“In vitro, CML LSCs were observed to be insensitive to imatinib, and, are presumed to be insensitive in vivo [7,8].”
BackgroundJuan, W. C., & Ong, S. T. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00007-9 · Cited by 13
Barachini, S., Montali, M., Burzi, I. S., Pardini, E., Infirri, G. S., Cassano, R. C., & Petrini, I. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105090 · Cited by 11
Chen, Y., Möbius, S., Riege, K., Hoffmann, S., Hochhaus, A., Ernst, T., & Rudolph, K. L. (2023) · Leukemia · doi:10.1038/s41375-023-01929-6 · Cited by 9
“Treatment with tyrosine kinase inhibitors (TKI) effectively removes the majority of leukemic cells and drives the disease into deep molecular remission, but residual CML cells remain and relapses occur in a significant percentage of patients after discontinuation of TKI treatment, suggesting survival of CML stem cells…”
BackgroundLaganà, A., Scalzulli, E., Bisegna, M. L., Carmosino, I., Ielo, C., Costa, A. N., Torrieri, L., Totaro, M., Martelli, M., & Breccia, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368822 · Cited by 12
“Hence, data from clinical trial seem to evidence that the chance of a stable TFR is similar between all the TKIs in patients who have maintained DMR for more than 2 years [35–37].”
Wu, L., Chen, X., Huang, L., Tian, J., Ke, F., Xu, J., Chen, Y., & Zheng, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123314 · Cited by 9
Genetic Events Other than BCR-ABL1
Neviani, P. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0194-x · Cited by 9
Chronic myeloid leukemia: the basis of treatment for tomorrow
Carella, A., Goldman, J. M., Martinelli, G., Melo, J. V., & Perrotti, D. (2011) · Haematologica · doi:10.3324/haematol.2011.052571 · Cited by 9
“In primitive CML cells, the apoptotic effect of FTY720 might not require BCR-ABL1 activity(7) which, as reported, is not essential for their survival.(10) Indeed, it seems that alternative signaling pathways which require the expression of BCR-ABL1 for their activation and/or maintenance are necessary for the effect o…”
Background
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.